GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » Price-to-Owner-Earnings

MDXG (MiMedx Group) Price-to-Owner-Earnings : 15.26 (As of Dec. 11, 2024)


View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group Price-to-Owner-Earnings?

As of today (2024-12-11), MiMedx Group's share price is $9.46. MiMedx Group's Owner Earnings per Share (TTM) ended in Sep. 2024 was $0.62. It's Price-to-Owner-Earnings for today is 15.26.


The historical rank and industry rank for MiMedx Group's Price-to-Owner-Earnings or its related term are showing as below:

MDXG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.2   Med: 82.47   Max: 9000
Current: 15.59

During the past 13 years, the highest Price-to-Owner-Earnings of MiMedx Group was 9000.00. The lowest was 4.20. And the median was 82.47.


MDXG's Price-to-Owner-Earnings is ranked better than
76.54% of 162 companies
in the Biotechnology industry
Industry Median: 31.44 vs MDXG: 15.59

As of today (2024-12-11), MiMedx Group's share price is $9.46. MiMedx Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $0.62. Therefore, MiMedx Group's PE Ratio (TTM) for today is 15.38.

As of today (2024-12-11), MiMedx Group's share price is $9.46. MiMedx Group's EPS without NRI for the trailing twelve months (TTM) ended in was $0.64. Therefore, MiMedx Group's PE Ratio without NRI for today is 14.90.

During the past 13 years, MiMedx Group's highest PE Ratio without NRI was 1978.33. The lowest was 2.98. And the median was 31.73.


MiMedx Group Price-to-Owner-Earnings Historical Data

The historical data trend for MiMedx Group's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group Price-to-Owner-Earnings Chart

MiMedx Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 25.64

MiMedx Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,290.00 25.64 20.59 12.33 9.58

Competitive Comparison of MiMedx Group's Price-to-Owner-Earnings

For the Biotechnology subindustry, MiMedx Group's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiMedx Group's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where MiMedx Group's Price-to-Owner-Earnings falls into.



MiMedx Group Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

MiMedx Group's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=9.46/0.62
=15.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MiMedx Group  (NAS:MDXG) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


MiMedx Group Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of MiMedx Group's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


MiMedx Group Business Description

Traded in Other Exchanges
N/A
Address
1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Executives
Hulse William Frank Iv officer: General Counsel 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow officer: Chief Operating Officer C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rice Doug officer: Chief Financial Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper officer: Chief Executive Officer BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein officer: EVP, Research and Development C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson officer: Chief Financial Officer BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan officer: Chief Accounting Officer 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Rohit Kashyap officer: EVP & Chief Commercial Officer 8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright director, officer: Chief Executive Officer C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves officer: SVP & Chief Compliance Officer 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner officer: SVP, Operations & Procurement 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani director 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604